Researchers Solve 50-Year-Old Challenge in Making Cancer Drug

Scientists have overcome production barriers that have plagued doxorubicin manufacturing since the 1970s by engineering bacteria that generate 180% more of the critical chemotherapy drug than current methods achieve. The breakthrough addresses molecular bottlenecks that forced pharmaceutical companies to rely on expensive, multi-step processes despite treating over one million cancer patients annually with the medication.

The advance could reshape how essential medicines get produced globally.

Doxorubicin has been essential to the treatment of breast cancer, bladder cancer, lymphomas, and carcinomas since gaining approval five decades ago. However, bacteria that naturally synthesize the compound do so extremely inefficiently, creating supply constraints and high costs that persist despite the drug’s widespread importance.

Keith Yamada from the University of Turku in Finland, who led the research, says the team uncovered several independent factors limiting drug formation and used targeted genetic modifications to enable affordable manufacturing meeting rising global demand.

Six laboratories spanning Finland, the United States, and the Netherlands collaborated to identify three critical production limitations. First, researchers discovered the synthesis enzyme requires specific “biological power supply” molecules called Fdx4 and FdR3 that deliver electron flow driving chemical reactions. Without adequate quantities of these redox partners, production stalls regardless of other favorable conditions in the bacterial cells.

Second, scientists found a protein named DnrV functions as a molecular sponge that binds and holds doxorubicin molecules as they accumulate. This sequestration prevents the drug from interfering with the very enzyme producing it, solving a feedback inhibition problem that previously limited yields.

Third, X-ray crystallography revealed the enzyme’s complete three-dimensional structure for the first time, showing doxorubicin binds in an unfavorable position inside the catalyst that significantly slows reaction rates.

Integrating these insights allowed the team to engineer bacterial strains addressing all three bottlenecks simultaneously. The optimized microbes boost the power supply molecules, express enhanced levels of the protective sponge protein, and operate efficiently despite structural constraints.

Production jumped 180% above industrial benchmarks while maintaining exceptional drug purity, demonstrating how understanding molecular mechanisms at fundamental levels enables dramatic manufacturing improvements.

Researchers launched Meta-Cells Oy at the University of Turku last year to commercialize the technology. The spin-out company aims to develop fully biosynthetic manufacturing methods for antibiotics and cancer medications, potentially creating cleaner and more reliable medicine supplies.

Current semi-synthetic approaches involve chemical modification steps that generate hazardous waste and require complex quality control procedures. Direct bacterial production could simplify manufacturing chains while reducing environmental impact and lowering costs.

The work appeared in Nature Communications and represents a potential shift for pharmaceutical manufacturing. As cancer treatment demands grow globally and supply security becomes increasingly important, production methods that nearly triple output from biological sources could improve drug access and affordability.

The approach may extend beyond doxorubicin to other complex therapeutic molecules where natural producers operate inefficiently, opening paths to sustainable medicine manufacturing at industrial scale.

It would be interesting to hear what leading cancer drug developers like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) think about this breakthrough that has occurred half a century after doxorubicin first emerged as a trusted form of therapy against several cancers.

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Austin, Texas
www.TinyGems.com
512.354.7000 Office
Editor@TinyGems.com

TinyGems is powered by IBN